pneumococcal vaccine 13-valent

For individuals 18 years and above, it is recommended for:
Active immunization to prevent pneumonia and invasive disease caused by S. pneumoniae serotypes 1, 4, 3, 5, 6B, 6A, 7F, 9V, 18C, 14, 19A, 23F, and 19F
The usual adult dose is 0.5 mL IM one time
Adults 19–64: Adults with specific medical issues are advised to use according to ACIP guidelines
Immunocompetent adults over 65: immunization needs are determined by collaborative decision-making between the patient and the practitioner (i.e., immunization is no longer routinely advised for all adults over 65)
adults with specific medical issues aged 19–64:
One dosage of PCV13 and one dose of PPSV23 should be given at least a year apart; repeat the regimen if you are over 65
Adults who are immunecompetent and over 65:
using collaborative clinical decision-making
When administering PCV13 and PPSV23 together, PCV13 should be given first and the two should wait at least a year between each other
Avoid giving out within the same visit
Considerations for Dosing
specific health issues affecting people aged 19 to 64:
Alcoholism
Cigarette smoking
CSF leak
Diabetes mellitus
Cochlear implant
Congenital or acquired asplenia
Chronic renal failure
Congenital or acquired immunodeficiencies
Generalized malignancy
Nephrotic syndrome
HIV infection
Sickle cell disease or other hemoglobinopathies
Lymphoma, hodgkin disease, leukemia, multiple myeloma
Iatrogenic immunosuppression
Solid organ transplant
Chronic heart, liver, or lung disease

Dose Adjustments

Limited data is available

Routine vaccination involves a 4-dose series administered at ages 2, 4, and 6 months, with an additional dose at ages 12-15 months
For individuals aged six weeks through 17 years, the vaccine is recommended for active immunization against invasive disease which S pneumoniae serotypes 1, 6B, 3, 4, 5, 6A, 9V, 7F, 9V, 14, 18C, 19F, 19A, 19F, and 23F cause
In the age group of 6 weeks through 5 years, the vaccine is also indicated for the otitis media prevention caused by S pneumoniae serotypes 4, 9V, 6B, 14, 19F, 18C, and 23F
The usual dose is 0.5 mL administered intramuscularly (IM)
For the most current vaccination schedules, refer to http://www.cdc.gov/vaccines/schedules/hcp/index.html
The PCV7 vaccine, designed initially to cover seven strains of pneumococcal bacteria, has undergone an update to the PCV13 vaccine, expanding its coverage to 13 strains
Completion of the PCV series, initiated with PCV7, is advised with the use of PCV13. For children aged 14–59 months who have completed an age-appropriate PCV7 series and for those aged 60–71 months with specific underlying medical conditions, an additional dose of PCV13 is recommended
The PCV vaccine is recommended for the following groups of children:
• Infants below 24 months should receive four doses of the vaccine, starting at two months
• Subsequent doses should be administered at four months and six months, with a final booster recommended at 12 to 15 months
• Children who miss these intervals should still receive the vaccine, with the number of doses and intervals contingent on the child's age
• Healthy children aged 2 through 4 years who did not complete the four-dose regimen should receive one dose of the vaccine
Additionally, the PPSV vaccine is recommended for adults aged 19 through 64 who smoke or have asthma and for individuals aged 2 through 64 undergoing treatments affecting the immune system (e.g., long-term steroid use, chemotherapy, or radiation therapy)
Furthermore, individuals aged 2 through 64 with specific health conditions impacting the immune system, such as Hodgkin's disease, HIV infection, lymphoma, kidney failure, leukemia, diabetes, and more, should be vaccinated with PPSV
For children aged six weeks to 5 years:
• Four doses of 0.5 mL each, administered intramuscularly (IM) at two months, four months, six months, and 12 to 15 months
For unvaccinated children aged seven months through 5 years:
• Aged 7–11 months when the first dosage was given: three 0.5 mL intramuscular injections in total
• Administer the first two doses with at least a 4-week interval
• Administer the third dose after the child turns one year old, with at least a 2-month gap after the second dose
• 12 to 23 months old during the initial dosage: Two dosages of 0.5 mL each, intramuscularly
• Administer the doses with at least a 2-month interval • Aged 24 months to 5 years at the first dose: One 0.5 mL dose, IM
For individuals aged 6 to 17 years:
• A single 0.5 mL dose, IM, is given once, with at least an 8-week gap after any previous pneumococcal vaccine